Drugs.com - Monthly Update April 2026

Drugs.com - Monthly Update April 2026

In this April 2026 Monthly Update edition, we highlight several FDA approvals that introduce first-of-their-kind therapies and improve access to existing treatments. * Foundayo (orforglipron): A first-of-its-kind small-molecule oral GLP-1 receptor agonist for chronic weight management without strict food or water requirements. * Otarmeni (lunsotogene parvec-cwha): An innovative gene therapy for pediatric and adult patients with OTOF-related genetic hearing loss. * Idvynso (doravirine and islatravir): A new once-daily, two-drug single-tablet regimen for adults with HIV-1 who are virologically suppressed. * Langlara (insulin glargine-aldy): A interchangeable biosimilar to Lantus for the treatment of type 1 and type 2 diabetes. Chapters: * (00:21) - Intro * (01:05) - Foundayo * (01:59) - Otarmeni * (02:55) - Idvynso * (03:50) - Langlara * (04:42) - Outro Follow Drugs.com: * X [https://twitter.com/drugscom], Facebook [https://www.facebook.com/Drugscom], YouTube [https://www.youtube.com/user/drugscom] * Sign up to our newsletters [https://www.drugs.com/newsletters/] * Download the app [https://www.drugs.com/apps/]

Drugs.com - Monthly Update March 2026

In this March 2026 edition of Drugs.com Monthly Update Podcast, learn about the FDA's latest approvals, including Wegovy HD for obesity, Icotyde for plaque psoriasis, Sotyktu for psoriatic arthritis, and Awiqli for type 2 diabetes.  Wegovy HD [https://www.drugs.com/mtm/wegovy-hd-pen.html] (semaglutide): A new high-dose option for adults managing obesity, showing significant weight loss in clinical trials. Icotyde [https://www.drugs.com/icotyde.html] (icotrokinra): The first oral IL-23 blocker approved to treat moderate-to-severe plaque psoriasis, providing a new oral treatment choice. Sotyktu [https://www.drugs.com/sotyktu.html] (deucravacitinib): An oral TYK2 inhibitor now approved for treating active psoriatic arthritis, addressing inflammation with a convenient dosing regimen. Awiqli [https://www.drugs.com/awiqli.html] (insulin isodec): The first once-weekly basal insulin for adults with type 2 diabetes. Chapters: * (00:21) - Intro * (01:00) - Wegovy HD * (02:10) - Icotyde * (03:12) - Sotyktu * (03:53) - Awiqli * (04:32) - Outro Follow Drugs.com: * X [https://twitter.com/drugscom], Facebook [https://www.facebook.com/Drugscom], Youtube [https://www.youtube.com/user/drugscom] * Sign up to our newsletters [https://www.drugs.com/newsletters/] * Download the app [https://www.drugs.com/apps/]

Drugs.com - Monthly Update February 2026

In this February 2026 edition of Drugs.com Monthly Update Podcast, learn about new options in weight management, type 2 diabetes, and lung cancer. Discover Eli Lilly's Zepbound KwikPen for simplified dosing in obesity management, the upcoming launch of the oral Ozempic pill for diabetes by Novo Nordisk, IBSA Pharma’s oral film formulation of sildenafil for erectile dysfunction called Vybrique, and the monthly Rybrevant Faspro injection for advanced NSCLC. * Zepbound KwikPen [https://www.drugs.com/zepbound.html] (tirzepatide): A new multidose Zepbound pen supplying 4 fixed weekly doses in one pen  * Ozempic pill [https://www.drugs.com/ozempic.html] (semaglutide): Discover the upcoming once-daily oral option for adults with type 2 diabetes to manage blood sugar and cardiovascular risks. * Rybrevant Faspro [https://www.drugs.com/rybrevant-faspro.html] (amivantamab and hyaluronidase-lpuj): Explore the benefits of a simplified, monthly injectable regimen for EGFR-mutated NSCLC. * Dupixent [https://www.drugs.com/dupixent.html] (dupilumab): The first approved therapy for allergic fungal rhinosinusitis, reducing the need for systemic steroids. * Vybrique [https://www.drugs.com/vybrique.html] (sildenafil): A new oral film formulation of sildenafil for erectile dysfunction. * Calquence [https://www.drugs.com/calquence.html] + Venetoclax [https://www.drugs.com/venetoclax.html] (acalabrutinib combination): This new all-oral regimen provides a targeted therapy for CLL, improving patient outcomes with a non-chemo approach. Chapters: * (00:00) - Intro * (00:20) - Overview Follow Drugs.com: * X [https://twitter.com/drugscom], Facebook [https://www.facebook.com/Drugscom], Youtube [https://www.youtube.com/user/drugscom] * Signup to our newsletters [https://www.drugs.com/newsletters/] * Download the app [https://www.drugs.com/apps/]

Drugs.com - Monthly Update January 2026

In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin. * Darzalex Faspro [https://www.drugs.com/darzalex.html] (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma. * Yuvezzi [https://www.drugs.com/yuvezzi.html] (carbachol and brimonidine tartrate), a novel combination eye drop for presbyopia. * Zycubo [https://www.drugs.com/zycubo.html] (copper histidinate), the first treatment for Menkes disease in children. * Nexplanon [https://www.drugs.com/nexplanon.html] (etonogestrel), a birth control implant with an extension of use for up to five years. * Afrezza [https://www.drugs.com/afrezza.html] (insulin human), an inhaled insulin, with updated dosing guidance. Chapters * (00:00) - Intro * (00:21) - Overview * (00:47) - Darzalex * (02:13) - Yuvezzi * (03:06) - Zycubo * (03:50) - Nexplanon * (04:35) - Afrezza * (05:09) - Outro Follow Drugs.com: * X [https://twitter.com/drugscom], Facebook [https://www.facebook.com/Drugscom], Youtube [https://www.youtube.com/user/drugscom] * Signup to our newsletters [https://www.drugs.com/newsletters/] * Download the app [https://www.drugs.com/apps/]

Drugs.com - Monthly Update December 2025

This month, discover the Wegovy tablet, the first oral GLP-1 weight loss medication to be approved, Myqorzo's long-awaited treatment for obstructive hypertrophic cardiomyopathy, and several other exciting new FDA approvals. Explore these key stories and more in our December 2025 round-up. * Wegovy [https://www.drugs.com/wegovy.html] (semaglutide) tablet, the first oral GLP-1 for weight loss, with significant efficacy in patient trials. * Myqorzo [https://www.drugs.com/myqorzo.html] (aficamten), a long-awaited and major addition to obstructive hypertrophic cardiomyopathy treatment that improves exercise capacity. * Exdensur [https://www.drugs.com/exdensur.html] (depemokimab-ulaa), a new long-term, add-on treatment for severe eosinophilic asthma with twice-yearly injections. * Jaypirca [https://www.drugs.com/jaypirca.html] (pirtobrutinib), a non-covalent BTK inhibitor whose approval has been extended to include chronic lymphocytic leukemia and small lymphocytic lymphoma. * Lerochol [https://www.drugs.com/lerochol.html] (lerodalcibep-liga), a third-generation, PCSK9 inhibitor for high cholesterol self-administered via a monthly injection. * Breyanzi [https://www.drugs.com/breyanzi.html] (lisocabtagene maraleucel), a CAR T cell therapy with extended approval to include relapsed or refractory marginal zone lymphoma. Chapters * (00:00) - Intro * (00:22) - Overview * (00:34) - Wegovy * (01:16) - Myqorzo * (02:07) - Exdensur * (02:56) - Jaypirca * (03:31) - Lerochol * (04:09) - Breyanzi * (04:46) - Outro Follow Drugs.com: * X [https://twitter.com/drugscom], Facebook [https://www.facebook.com/Drugscom], Youtube [https://www.youtube.com/user/drugscom] * Signup to our newsletters [https://www.drugs.com/newsletters/] * Download the app [https://www.drugs.com/apps/]